Prestige Consumer Healthcare Closes LaCorium Deal, Prices $400M Notes
PBH sealed the LaCorium Health acquisition, tapped debt markets for $400M, and set an August earnings date all in one shot.
Prestige Consumer Healthcare (NYSE: PBH) just had a busy Monday. The Tarrytown, N.Y.-based OTC brand operator closed its previously announced acquisition of LaCorium Health, priced a $400 million private senior notes offering, and dropped an earnings date — all in a single press release. That's a lot of corporate action packed into one announcement.
The $400 million senior notes deal is the one to watch. Debt-financed acquisitions put pressure on free cash flow, and the market will want to see exactly what rate PBH locked in and how the new leverage stacks up against EBITDA. Senior notes in a private offering typically carry fixed rates, so the cost of capital here is baked in — for better or worse.
Read more ANV Group Closes Iris Insurance Brokers Deal in London →
LaCorium Health adds to Prestige's portfolio of consumer healthcare brands. The company has a well-worn playbook: buy niche OTC brands, squeeze out efficiencies, and let the cash flow. Whether LaCorium fits that mold is the real question traders should be asking before the next earnings call.
Mark your calendar for August 6, 2026. That's when Prestige reports first quarter fiscal 2027 results, and it'll be the first real look at how the combined business is performing post-close. Expect management to walk through integration costs, updated leverage metrics, and any early revenue contribution from the new acquisition. That print could move the stock.
Continue reading at GlobalNewswire.
